Recent Updates
Recently added Catalysts
NNOX Positive Sentiment Score: 70/100

Nanox Files 2023 Annual Report on Form 20-F PETACH TIKVA, Israel--(BUSINESS WIRE)

Key Takeaway: Nanox Imaging Ltd (NNOX) has filed its 2023 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. This report contains the company's audited consolidated financial statements for the fiscal year ending December 31, 2023. Nanox focuses on utilizing its proprietary medical imaging technology to improve accessibility and affordability in diagnostic medicine globally. The report can be accessed through the SEC and Nanox's official website, with hard copies available upon request.

Market Sentiment Analysis

POSITIVE FACTORS

  • The annual report showcases Nanox's audited financial health.
  • Nanox's innovative technology aims to enhance access to medical imaging.
  • The company is positioning itself as a leader in affordable diagnostic solutions.

Full Press Release Details

Nanox Files 2023 Annual Report on Form 20-F
PETACH TIKVA, Israel--(BUSINESS
WIRE)-April 22, 2024-- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative
medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended
December 31, 2023, with the U.S. Securities and Exchange Commission ("SEC") on April 22, 2024. The annual report on Form
20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at
https://www.sec.gov/ and on the Company's website at https://www.nanox.vision/ under "Financials"
in the Investors section.
The Company will provide a hard copy of its annual
report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be
directed to Investor Relations, at IR@nanox.vision.
Nanox (NASDAQ: NNOX) is focused on applying its
proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox's
vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to
improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately,
to save lives. The Nanox ecosystem includes Nanox.ARC- a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly;
an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease
(Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox's subsidiary,
USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform
(Nanox.MARKETPLACE). Together, Nanox's products and services create a worldwide, innovative, and comprehensive solution that connects
medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.

Frequently Asked Questions

What is the purpose of Nanox's 2023 Annual Report?

The report provides audited consolidated financial statements for the fiscal year.

Where can I access the annual report on Form 20-F?

It's available on the SEC's website and Nanox's website under 'Financials.'

How can shareholders request a hard copy of the annual report?

Shareholders can request a free hard copy by contacting Investor Relations via email.

What is Nanox's primary focus in medical imaging?

Nanox aims to make diagnostic medicine more accessible and affordable worldwide.

What products are included in the Nanox ecosystem?

Products include Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE.

Last updated: Apr 22, 2024